+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06362252

Study of Ifinatamab Deruxtecan with Atezolizumab, With or Without Carboplatin, as First-Line Treatment for Extensive Stage-Small Cell Lung Cancer

Led by Daiichi Sankyo · Updated on 2026-10-01

123

Participants Needed

58

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd combined with the immune checkpoint inhibitor atezolizumab, with or without carboplatin, in adults with extensive stage-small cell lung cancer ES-SCLC. This study includes two parts Part A focuses on safety and dose finding, while Part B aims to optimize the dose of I-DXd in combination with atezolizumab and carboplatin. The study targets participants in the first-line treatment setting of ES-SCLC. Participants may be assigned to different groups depending on prior treatment. Some will receive maintenance therapy with I-DXd and atezolizumab after standard induction therapy, while others who are newly diagnosed and treatment-naive will receive induction therapy combining I-DXd, atezolizumab, and carboplatin followed by maintenance therapy. The doses of I-DXd vary between 8 mgkg and 12 mgkg given intravenously every three weeks. The study includes a safety monitoring period when dosing the first participants. During the study, participants will have regular visits for treatment administration and safety assessments. Researchers will monitor adverse events, treatment tolerability, and detailed measures such as progression-free survival, response rates, and overall survival over approximately 37 months. Additional evaluations include imaging scans, biopsies, laboratory tests, and pharmacokinetic blood sampling. Participants are expected to comply with study procedures, including biopsies for some groups and contraception requirements for those of childbearing potential.

CONDITIONS

Brief Title

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Research Team

(

(US) Daiichi Sankyo Contact for Clinical Trial Information

(

(Asia) Daiichi Sankyo Contact for Clinical Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here